

Supporting information

Direct C-2 acylation of indoles with toluene derivatives *via* Pd(II)-catalyzed direct C-H activation

Yaping Zhao,^c Upendra K. Sharma,^a Felix Schröder,^a Nandini Sharma,^{a,*} Gonghua Song^c and Erik V. Van der Eycken^{a,b,*}

^aLaboratory for Organic & Microwave-Assisted Chemistry (LOMAC), Department of Chemistry, University of Leuven (KU Leuven), Celestijnenlaan 200 F, B-3001 Leuven, Belgium.

^bPeoples Friendship University of Russia (RUDN University) 6 Miklukho-Maklaya street, Moscow, 117198, Russia.

^cShanghai Key Laboratory of Chemical Biology, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.

Email: nsharma023@gmail.com or erik.vandereycken@chem.kuleuven.be

Table of Contents

This page.....	1
General experimental procedures.....	2
Characterization of Products.....	3-8
Copies of ¹ H and ¹³ C NMR spectra.....	9-29

General experimental procedure

NMR spectra were recorded on a 300 MHz instrument using CDCl₃ as solvent unless and otherwise stated (s = singlet, d = doublet, t = triplet, m = multiplet). The ¹H and ¹³C chemical shifts are reported in parts per million relative to tetramethylsilane as an internal standard. For the Mass spectrometry, ion source temperature was 150-250 °C, as required. High-resolution EI-mass spectra were performed with a resolution of 10,000. For chromatography, analytical TLC plates and 70-230 mesh silica gel were used. All the solvents and chemicals were purchased and used as available.


Typical experimental procedure

1-(pyrimidin-2-yl)-1*H*-indole (1 equiv, 0.2 mmol), PdBr₂ (10 mol%, 0.02 mmol), PivOH (0.5 equiv), PhCl (0.5 mL), toluene (1.5 mL), TBHP (5 equiv, 1.0 mmol), were consecutively loaded to an oven dried 10 mL screw cap vial equipped with a magnetic stirring bar and then stirred at 120 °C for 24 h. The resulting reaction mixture was cooled to the ambient temperature and subjected to the column chromatography to afford desired 2-oxindole. The products were further identified by ¹H NMR, ¹³C NMR.

Removal of directing group


An oven-dried 10 mL screw-cap vial was charged with a mixture of **3c** (65.8 mg, 0.3 mmol), DMSO (2.0 mL) and EtONa (61.2 mg, 0.90 mmol), and the reaction mixture was stirred at 100 °C under nitrogen atmosphere for 24 h. After cooling to ambient temperature, the reaction mixture was diluted with EtOAc and washed with H₂O. The aqueous phase was extracted with EtOAc, and the combined organic phase was dried over Na₂SO₄. After filtration and evaporation under reduced pressure, the residue was purified by flash column chromatography (petroleum ether/ethyl acetate) on silica gel to give the product **3cc**.

Characterization of products




phenyl(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)methanone(3a)

¹H NMR (300 MHz, CDCl₃) δ 8.64 (d, *J* = 4.8 Hz, 2H), 8.40 (dd, *J* = 8.5, 0.8 Hz, 1H), 7.97 (dd, *J* = 8.3, 1.3 Hz, 2H), 7.71 (d, *J* = 7.8 Hz, 1H), 7.59–7.52 (m, 1H), 7.48–7.41 (m, 3H), 7.32–7.27 (m, 1H), 7.13 (d, *J* = 0.7 Hz, 1H), 7.07 (t, *J* = 4.8 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 187.6, 157.9, 157.3, 138.3, 138.0, 137.2, 132.7, 129.6, 128.3, 128.0, 126.5, 122.8, 122.5, 117.4, 115.4, 114.2. HRMS (ESI) for C₁₉H₁₄N₃O [M+H]⁺ calculated 300.1131, found 300.1136.




(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)(*p*-tolyl)methanone(3b)

¹H NMR (300 MHz, CDCl₃) δ 8.64 (d, *J* = 4.8 Hz, 2H), 8.40 (dd, *J* = 8.5, 0.8 Hz, 1H), 7.89 (d, *J* = 8.2 Hz, 2H), 7.70 (d, *J* = 7.8 Hz, 1H), 7.44 (ddd, *J* = 8.5, 7.1, 1.3 Hz, 1H), 7.32–7.27 (m, 1H), 7.25 (d, *J* = 7.3 Hz, 2H), 7.10 (d, *J* = 0.7 Hz, 1H), 7.06 (t, *J* = 4.8 Hz, 1H), 2.42 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 187.4, 157.9, 157.4, 143.5, 138.2, 137.4, 135.4, 129.7, 129.1, 128.1, 126.3, 122.8, 122.4, 117.3, 115.0, 114.2, 21.7. HRMS (ESI) for C₂₀H₁₅N₃O [M+H]⁺ calculated 314.1288, found 314.1291.



(4-methoxyphenyl)(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)methanone (3c)


¹H NMR (300 MHz, CDCl₃) δ 8.65 (d, *J* = 4.8 Hz, 2H), 8.40 (dq, *J* = 8.4, 0.9 Hz, 1H), 8.04–7.94 (m, 2H), 7.70 (dt, *J* = 7.8, 1.0 Hz, 1H), 7.43 (ddd, *J* = 8.5, 7.1, 1.3 Hz, 1H), 7.34–7.26 (m, 1H), 7.13–7.03 (m, 2H), 6.98–6.90 (m, 2H), 3.87 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 186.5, 163.4, 157.9, 157.4, 138.1, 137.4, 131.9, 130.8, 128.1, 126.2, 122.7, 122.3, 117.3, 114.6, 114.2, 113.6, 55.5. HRMS (ESI) for C₂₀H₁₅N₃O₂ [M+H]⁺ calculated 330.1237, found 330.1234.



(4-fluorophenyl)(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)methanone(3d)


¹H NMR (300 MHz, CDCl₃) δ 8.64 (d, *J* = 4.8 Hz, 2H), 8.41 (dd, *J* = 8.5, 0.7 Hz, 1H), 8.01 (ddd, *J* = 8.9, 5.2, 2.5 Hz, 2H), 7.71 (d, *J* = 7.9 Hz, 1H), 7.46 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1H), 7.34–7.27 (m, 1H), 7.17–7.06 (m, 4H). ¹³C NMR (75 MHz, CDCl₃) δ 186.2, 158.0, 157.2, 138.3, 136.9, 132.1, 132.0, 127.9, 126.6, 122.9, 122.5, 117.4, 115.7, 115.4, 115.3,

114.3.HRMS (ESI) for C₁₉H₁₂N₃O [M+H]⁺ calculated 318.1037, found 318.1042.




(4-bromophenyl)(1-(pyrimidin-2-yl)-1H-indol-2-yl)methanone(3e)

¹H NMR (300 MHz, CDCl₃) δ 8.64 (d, J = 4.8 Hz, 2H), 8.40 (dd, J = 8.5, 0.8 Hz, 1H), 7.97 (dd, J = 8.3, 1.3 Hz, 2H), 7.71 (d, J = 7.8 Hz, 1H), 7.59–7.52 (m, 2H), 7.48–7.41 (m, 1H), 7.32–7.27 (m, 1H), 7.13 (d, J = 0.7 Hz, 1H), 7.07 (t, J = 4.8 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 186.6, 157.9, 157.2, 138.3, 136.9, 136.7, 131.7, 130.9, 128.0, 127.8, 126.7, 122.9, 122.5, 117.4, 115.3, 114.4. HRMS (ESI) for C₁₉H₁₂BrN₃O [M+H]⁺ calculated 378.0237, found 378.0240.




(4-iodophenyl)(1-(pyrimidin-2-yl)-1H-indol-2-yl)methanone(3f)

¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 2H), 8.42 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.69 (t, J = 10.4 Hz, 3H), 7.46 (t, J = 7.3 Hz, 1H), 7.31 (d, J = 7.4 Hz, 1H), 7.09 (d, J = 11.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 186.8, 157.9, 157.2, 138.3, 137.7, 137.4, 136.7, 130.9, 128.0, 126.7, 122.9, 122.5, 117.4, 115.3, 114.4, 100.5. HRMS (ESI) for C₁₉H₁₂I₂N₃O [M+H]⁺ calculated 426.0100, found 426.0094.




(1-(pyrimidin-2-yl)-1H-indol-2-yl)(o-tolyl)methanone(3i)

¹H NMR (300 MHz, CDCl₃) δ 8.68 (d, J = 4.8 Hz, 2H), 8.29 (dq, J = 8.5, 0.9 Hz, 1H), 7.68 (dt, J = 7.9, 1.0 Hz, 1H), 7.56 (dd, J = 7.6, 1.4 Hz, 1H), 7.43 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.34 (td, J = 7.5, 1.5 Hz, 1H), 7.31–7.26 (m, 1H), 7.26–7.22 (m, 1H), 7.20–7.12 (m, 1H), 7.12–7.05 (m, 2H), 2.56 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 189.2, 157.9, 157.5, 138.7, 138.1, 131.2, 131.1, 130.3, 129.9, 127.8, 127.6, 126.7, 126.1, 125.1, 122.8, 122.7, 117.6, 116.3, 113.9, 20.4. HRMS (ESI) for C₂₀H₁₅N₃O [M+H]⁺ calculated 314.1288, found 314.1293.




(3,5-dimethylphenyl)(1-(pyrimidin-2-yl)-1H-indol-2-yl)methanone (3j)

¹H NMR (300 MHz, CDCl₃) δ 8.66 (d, J = 4.8 Hz, 2H), 8.37 (dd, J = 8.5, 0.7 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.62 (s, 2H), 7.44 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.34–7.26 (m, 1H), 7.21 (s, 1H), 7.12–7.05 (m, 2H), 2.36 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 187.9, 157.9, 157.4, 138.3, 138.0, 137.9, 137.4, 134.5, 127.9, 127.5, 126.4, 122.7, 122.5, 117.4, 115.3, 114.1, 21.2. HRMS (ESI) for C₂₁H₁₇N₃O [M+H]⁺ calculated 328.1444, found 328.1449.




naphthalen-1-yl(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)methanone(3k)

¹H NMR (300 MHz, CDCl₃) δ 8.74–8.67 (m, 1H), 8.54 (d, J = 4.8 Hz, 2H), 8.37 (dq, J = 8.5, 0.9 Hz, 1H), 7.97–7.83 (m, 2H), 7.79–7.66 (m, 2H), 7.65–7.50 (m, 2H), 7.49–7.35 (m, 2H), 7.29 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 7.16 (d, J = 0.9 Hz, 1H), 6.96 (t, J = 4.8 Hz, 1H). **¹³C NMR** (101 MHz, CDCl₃) δ 188.8, 157.8, 157.3, 138.9, 138.5, 136.0, 133.7, 132.3, 131.1, 129.0, 128.2, 127.9, 127.6, 126.7, 126.4, 126.1, 124.2, 122.8, 122.6, 117.3, 116.2, 114.2. HRMS (ESI) for C₂₃H₁₅N₃O [M+H]⁺ calculated 350.1288, found 350.1284.




(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)(*m*-tolyl)methanone(3l)

¹H NMR (300 MHz, CDCl₃) δ 8.65 (d, J = 4.8 Hz, 2H), 8.38 (dd, J = 8.5, 0.9 Hz, 1H), 7.81 (dq, J = 1.7, 0.8 Hz, 1H), 7.78 (dd, J = 7.2, 1.8 Hz, 1H), 7.71 (dt, J = 7.9, 1.0 Hz, 1H), 7.44 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.40–7.26 (m, 3H), 7.12 (d, J = 0.8 Hz, 1H), 7.08 (t, J = 4.8 Hz, 1H), 2.40 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 187.7, 157.9, 157.4, 138.3, 138.2, 137.9, 137.3, 133.6, 130.1, 128.2, 128.0, 126.9, 126.5, 122.8, 122.5, 117.4, 115.4, 114.2, 21.3. HRMS (ESI) for C₂₀H₁₅N₃O [M+H]⁺ calculated 314.1288, found 314.1284.



(3-fluorophenyl)(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)methanone (3m)


¹H NMR (300 MHz, CDCl₃) δ 8.65 (d, J = 4.9 Hz, 2H), 8.42 (dd, J = 8.5, 0.9 Hz, 1H), 7.78–7.63 (m, 3H), 7.51–7.36 (m, 2H), 7.31 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 7.27–7.21 (m, 1H), 7.15 (d, J = 0.8 Hz, 1H), 7.08 (t, J = 4.8 Hz, 1H). **¹³C NMR** (101 MHz, CDCl₃) δ 186.2, 163.9, 161.4, 157.9, 157.2, 140.2, 140.1, 138.3, 136.7, 130.0, 129.9, 127.9, 126.7, 125.3, 125.2, 122.9, 122.6, 119.8, 119.5, 117.4, 116.2, 115.9, 115.6, 114.4. HRMS (ESI) for C₁₉H₁₂FN₃O [M+H]⁺ calculated 318.1037, found 318.1035.



(3-bromophenyl)(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)methanone (3n)


¹H NMR (300 MHz, CDCl₃) δ 8.65 (d, J = 4.8 Hz, 2H), 8.42 (dq, J = 8.5, 0.9 Hz, 1H), 8.13 (t, J = 1.8 Hz, 1H), 7.87 (ddd, J = 7.7, 1.6, 1.1 Hz, 1H), 7.76–7.65 (m, 2H), 7.47 (ddd, J = 8.5, 7.2, 1.3 Hz, 1H), 7.36–7.28 (m, 2H), 7.14 (d, J = 0.8 Hz, 1H), 7.09 (t, J = 4.9 Hz, 1H). **¹³C NMR** (101 MHz, CDCl₃) δ 185.9, 157.9, 157.2, 139.9, 138.4, 136.5, 135.5, 132.6, 129.9, 128.0, 127.9, 126.8, 122.9, 122.6, 122.6, 117.4, 115.7, 114.4. HRMS (ESI) for C₁₉H₁₂BrN₃O [M+H]⁺ calculated

378.0237, found 378.0236.




(3-iodophenyl)(1-(pyrimidin-2-yl)-1H-indol-2-yl)methanone (3o)

¹H NMR (300 MHz, CDCl₃) δ 8.66 (d, J = 4.8 Hz, 2H), 8.41 (dq, J = 8.5, 0.9 Hz, 1H), 8.33 (t, J = 1.7 Hz, 1H), 7.95–7.83 (m, 2H), 7.72 (dt, J = 7.9, 1.0 Hz, 1H), 7.46 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.31 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 7.18 (t, J = 7.8 Hz, 1H), 7.13 (d, J = 0.8 Hz, 1H), 7.10 (t, J = 4.8 Hz, 1H). **¹³C NMR** (101 MHz, CDCl₃) δ 185.9, 157.9, 157.2, 141.4, 139.82, 138.4, 138.2, 136.5, 130.0, 128.7, 127.9, 126.8, 122.9, 122.6, 117.5, 115.8, 114.3, 94.1. HRMS (ESI) for C₁₉H₁₂N₃O [M+H]⁺ calculated 426.0100, found 426.0097.




(3-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)(phenyl)methanone (3p)

¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J = 8.4 Hz, 1H), 8.46 (d, J = 4.8 Hz, 2H), 7.78 (d, J = 7.4 Hz, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.51–7.39 (m, 2H), 7.33 (q, J = 7.4 Hz, 3H), 6.85 (t, J = 4.8 Hz, 1H), 2.37 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 189.47, 157.6, 157.1, 139.3, 136.4, 133.3, 132.3, 130.3, 128.6, 128.3, 126.1, 122.6, 121.7, 120.2, 116.1, 115.2, 9.4. HRMS (ESI) for C₂₀H₁₅N₃O [M+H]⁺ calculated 314.1288, found 314.1284.




(5-methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl)(phenyl)methanone (3q)

¹H NMR (300 MHz, CDCl₃) δ 8.59 (d, J = 4.8 Hz, 2H), 8.34 (d, J = 9.0 Hz, 1H), 7.98–7.91 (m, 2H), 7.57–7.49 (m, 1H), 7.46–7.39 (m, 2H), 7.13–7.06 (m, 2H), 7.05 (d, J = 0.6 Hz, 1H), 7.02 (t, J = 4.8 Hz, 1H), 3.88 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 187.6, 157.9, 157.2, 156.0, 138.1, 137.7, 133.2, 132.6, 129.5, 128.7, 128.3, 117.1, 116.5, 115.5, 114.9, 103.5, 55.7. HRMS (ESI) for C₂₀H₁₅N₃O₂ [M+H]⁺ calculated 330.1237, found 330.1237.




(5-fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)(phenyl)methanone (3r)

¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 2H), 8.46–8.37 (m, 1H), 7.94 (d, J = 6.9 Hz, 2H), 7.55 (s, 1H), 7.44 (d, J = 6.8 Hz, 2H), 7.34 (d, J = 9.0 Hz, 1H), 7.17 (t, J = 9.0 Hz, 1H), 7.05 (s, 2H). **¹³C NMR** (101 MHz, CDCl₃) δ 187.6, 160.4, 158.0, 157.9, 157.0, 138.5, 137.8, 134.5, 132.8, 129.5, 128.6, 128.6, 128.6, 128.4, 127.6, 126.9, 117.4, 115.8, 115.7, 114.7, 114.5, 114.2, 107.3, 107.1. HRMS (ESI) for C₁₉H₁₂FN₃O [M+H]⁺ calculated 318.1037, found 318.1036.




(5-bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)(phenyl)methanone (3s)

¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 2H), 8.33 (d, *J* = 8.8 Hz, 1H), 7.94 (d, *J* = 6.5 Hz, 2H), 7.82 (s, 1H), 7.60–7.48 (m, 2H), 7.48–7.26 (m, 2H), 7.06 (s, 1H), 7.02 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 187.4, 157.9, 156.9, 138.1, 137.7, 136.6, 132.9, 129.7, 129.5, 129.1, 128.4, 124.7, 117.6, 116.1, 115.9, 113.6. HRMS (ESI) for C₁₉H₁₂BrN₃O [M+H]⁺ calculated 378.0237, found 378.0230.




(4-bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)(phenyl)methanone (3t)

¹H NMR (400 MHz, CDCl₃) δ 8.64 (s, 2H), 8.35 (d, *J* = 8.4 Hz, 1H), 7.98 (d, *J* = 7.0 Hz, 2H), 7.57 (d, *J* = 6.6 Hz, 1H), 7.46 (d, *J* = 7.0 Hz, 3H), 7.29 (t, *J* = 10.6 Hz, 1H), 7.16 (s, 1H), 7.10 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 187.3, 158.1, 157.1, 138.3, 137.6, 137.5, 132.9, 129.6, 128.8, 128.5, 127.2, 125.7, 117.8, 116.1, 114.5, 113.4. HRMS (ESI) for C₁₉H₁₂BrN₃O [M+H]⁺ calculated 378.0237, found 378.0240.




2-benzoyl-1-(pyrimidin-2-yl)-1H-indole-4-carbonitrile (3u)

¹H NMR (300 MHz, CDCl₃) δ 8.72–8.63 (m, 3H), 8.04–7.95 (m, 2H), 7.68–7.59 (m, 2H), 7.50 (ddd, *J* = 8.5, 7.2, 1.1 Hz, 3H), 7.27 (d, *J* = 0.9 Hz, 1H), 7.16 (t, *J* = 4.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 187.20, 158.19, 156.69, 139.00, 137.48, 137.14, 133.35, 129.70, 129.41, 128.59, 127.77, 125.79, 119.35, 118.19, 117.66, 111.76, 105.08. HRMS (ESI) for C₂₀H₁₂N₄O [M+H]⁺ calculated 325.1084, found 325.1085.




(6-bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)(phenyl)methanone (3v)

¹H NMR (300 MHz, CDCl₃) δ 8.67–8.59 (m, 3H), 7.99–7.91 (m, 2H), 7.60–7.51 (m, 2H), 7.49–7.37 (m, 3H), 7.10–7.05 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 187.3, 158.0, 156.9, 138.6, 137.7, 137.6, 132.8, 129.5, 128.4, 126.8, 126.3, 123.5, 120.3, 117.6, 117.5, 114.6. HRMS (ESI) for C₁₉H₁₂BrN₃O [M+H]⁺ calculated 378.0237, found 378.0238.



(7-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)(phenyl)methanone (3w)

¹H NMR (300 MHz, CDCl₃) δ 8.88 (d, *J* = 4.9 Hz, 2H), 7.95–7.90 (m, 2H), 7.62–7.56 (m, 2H), 7.52–7.45 (m, 2H), 7.43 (t, *J* = 4.9 Hz, 1H), 7.21 (s, 1H), 7.15–7.11 (m, 2H), 1.97 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 187.1, 159.8, 158.2, 138.4, 138.3, 136.1, 132.4, 129.7, 129.3, 128.3, 127.3, 122.5, 121.9, 121.1, 120.2, 116.5, 19.4. HRMS (ESI) for C₂₀H₁₅N₃O [M+H]⁺ calculated 314.1288, found 314.1288.



(1H-indol-2-yl)(4-methoxyphenyl)methanone (3cc)


¹H NMR (400 MHz, Chloroform-d) δ 9.32 (s, 1H), 8.04 (d, *J* = 8.8 Hz, 2H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.48 (d, *J* = 8.3 Hz, 1H), 7.37 (t, *J* = 7.7 Hz, 1H), 7.21 – 7.12 (m, 2H), 7.03 (d, *J* = 8.8 Hz, 2H), 3.91 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 185.9, 163.4, 137.4, 134.6, 131.7, 130.8, 127.9, 126.3, 123.2, 121.1, 113.9, 112.2, 111.9, 77.2, 55.7.

N#Cc1cccnc1N2C(=O)c3ccccc3c2c4ccccc4



Chemical structure: 1-(pyridin-2-yl)-2-phenyl-1H-indole-3-carboxamide

¹H NMR spectrum (CDCl₃) showing peaks in the aromatic region (7.0-8.7 ppm) and a reference peak at 0.0 ppm. Integration values are provided below the peaks.



Chemical Shift (ppm)	Integration
8.647, 8.631	1.97
8.414, 8.386, 8.384	1.00
7.985, 7.962, 7.957, 7.953, 7.938	2.01
7.852, 7.578, 7.573, 7.561, 7.553, 7.546, 7.533, 7.529, 7.514, 7.477, 7.473, 7.467, 7.463, 7.454, 7.449, 7.446, 7.442, 7.428, 7.421, 7.418, 7.414, 7.323, 7.319, 7.296, 7.273, 7.269, 7.254, 7.132, 7.082, 7.065, 7.049	1.03, 1.12, 3.08, 1.24, 1.06





9





3b





3c





3d





3e





3f





3i





3j





3k





31





3m





3n





30









3q




3r





3s





3t



3u



3v



3w

